BR112013005772A2 - composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêutica - Google Patents
composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêuticaInfo
- Publication number
- BR112013005772A2 BR112013005772A2 BR112013005772A BR112013005772A BR112013005772A2 BR 112013005772 A2 BR112013005772 A2 BR 112013005772A2 BR 112013005772 A BR112013005772 A BR 112013005772A BR 112013005772 A BR112013005772 A BR 112013005772A BR 112013005772 A2 BR112013005772 A2 BR 112013005772A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- pharmaceutical composition
- rifaximin
- treating
- preparing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title 1
- 229960003040 rifaximin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2522MU2010 | 2010-09-13 | ||
| IN2539MU2010 | 2010-09-14 | ||
| PCT/GB2011/000785 WO2012035283A1 (en) | 2010-09-13 | 2011-05-23 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013005772A2 true BR112013005772A2 (pt) | 2019-09-24 |
Family
ID=44169144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013005772A BR112013005772A2 (pt) | 2010-09-13 | 2011-05-23 | composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130315988A1 (enExample) |
| EP (1) | EP2616044A1 (enExample) |
| JP (1) | JP2013537182A (enExample) |
| KR (1) | KR20140029356A (enExample) |
| CN (1) | CN103221032A (enExample) |
| AU (1) | AU2011303715A1 (enExample) |
| BR (1) | BR112013005772A2 (enExample) |
| CA (1) | CA2810598A1 (enExample) |
| MX (1) | MX2013002802A (enExample) |
| NZ (1) | NZ607935A (enExample) |
| RU (1) | RU2013113752A (enExample) |
| WO (1) | WO2012035283A1 (enExample) |
| ZA (1) | ZA201301920B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| GB201306980D0 (en) * | 2013-04-17 | 2013-05-29 | Blueberry Therapeutics Ltd | Methods |
| IN2014MU00916A (enExample) * | 2014-03-20 | 2015-09-25 | Cipla Ltd | |
| ES2742106T3 (es) | 2014-05-12 | 2020-02-13 | Alfasigma Spa | Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma |
| US20170202850A1 (en) | 2014-07-21 | 2017-07-20 | Hiroaki Serizawa | Ophthalmic compositions of rifamycins and uses thereof |
| EP3525825B1 (en) * | 2016-10-14 | 2024-03-20 | Cipla Limited | Pharmaceutical compositions comprising rifaximin |
| US20220184095A1 (en) * | 2019-04-22 | 2022-06-16 | Mylan Specialty L.P. | Meloxicam co-crystal compositions |
| EP4171520A1 (en) * | 2020-06-26 | 2023-05-03 | Bausch Health Ireland Limited | Targeted release rifaximin compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| CN100490790C (zh) * | 2007-04-28 | 2009-05-27 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
| JP5755878B2 (ja) * | 2007-07-06 | 2015-07-29 | ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | リファキシミンの薬剤組成物 |
| JP2009137922A (ja) * | 2007-11-16 | 2009-06-25 | Kaneka Corp | リファマイシン誘導体を傷害組織にデリバリーする製剤 |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| KR101906177B1 (ko) | 2008-12-10 | 2018-10-10 | 시플라 리미티드 | 리팍시민 복합체 |
-
2011
- 2011-05-23 CA CA2810598A patent/CA2810598A1/en not_active Abandoned
- 2011-05-23 EP EP11724702.3A patent/EP2616044A1/en not_active Withdrawn
- 2011-05-23 RU RU2013113752/15A patent/RU2013113752A/ru not_active Application Discontinuation
- 2011-05-23 WO PCT/GB2011/000785 patent/WO2012035283A1/en not_active Ceased
- 2011-05-23 NZ NZ607935A patent/NZ607935A/en not_active IP Right Cessation
- 2011-05-23 BR BR112013005772A patent/BR112013005772A2/pt not_active IP Right Cessation
- 2011-05-23 KR KR1020137007569A patent/KR20140029356A/ko not_active Withdrawn
- 2011-05-23 AU AU2011303715A patent/AU2011303715A1/en not_active Abandoned
- 2011-05-23 CN CN201180054627XA patent/CN103221032A/zh active Pending
- 2011-05-23 US US13/822,478 patent/US20130315988A1/en not_active Abandoned
- 2011-05-23 JP JP2013527670A patent/JP2013537182A/ja not_active Ceased
- 2011-05-23 MX MX2013002802A patent/MX2013002802A/es not_active Application Discontinuation
-
2013
- 2013-03-12 ZA ZA2013/01920A patent/ZA201301920B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013113752A (ru) | 2014-10-20 |
| CA2810598A1 (en) | 2012-03-22 |
| CN103221032A (zh) | 2013-07-24 |
| AU2011303715A1 (en) | 2013-04-04 |
| US20130315988A1 (en) | 2013-11-28 |
| NZ607935A (en) | 2015-01-30 |
| WO2012035283A8 (en) | 2013-08-22 |
| JP2013537182A (ja) | 2013-09-30 |
| EP2616044A1 (en) | 2013-07-24 |
| ZA201301920B (en) | 2013-10-30 |
| MX2013002802A (es) | 2013-06-03 |
| KR20140029356A (ko) | 2014-03-10 |
| WO2012035283A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013005772A2 (pt) | composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêutica | |
| BR112014010391A2 (pt) | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica | |
| BR112012026843A2 (pt) | composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv | |
| BR112014003296A2 (pt) | composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto | |
| FI20105606L (fi) | Hiomatuote ja menetelmä tällaisen valmistamiseksi | |
| PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| IL245348B (en) | Compounds for the treatment of paramyxoviridae virus infections | |
| BR112014010439A2 (pt) | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica | |
| LT2729151T (lt) | Farmacinė kompozicija, gydymo būdai ir jų panaudojimas | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| CO6791606A2 (es) | Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| EP2539416A4 (en) | Abrasive articles, method for their preparation and method of their use | |
| BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
| PT2736488E (pt) | Composições farmacêuticas contendo rifaximina, processos para a sua preparação e sua utilização no tratamento de infeções vaginais | |
| AP2015008599A0 (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
| BR112013014540A8 (pt) | artigo absorvente e método para preparar o mesmo | |
| PH12013501838A1 (en) | Cement composition and method for producing the same | |
| ZA201309559B (en) | Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof | |
| BRPI1008340A2 (pt) | forma cristalina, composição farmacêutica, processos para fabricar uma composição farmacêutica e uma forma, uso da forma cristalina, e, método para tratar uma condição de doença | |
| BR112013006857A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais | |
| BR112013022930A2 (pt) | composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica | |
| BR112014030949A2 (pt) | "composição, processo para o tratamento cosmético e uso de uma composição" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: CIPLA LIMITED (IN) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |